Receptor Dimerization Assays

Quantitative assays for receptor dimer formation

Ligand-induced receptor dimerization is the first step following receptor activation and the most proximal and reliable indicator of receptor activation. Until now, these interactions have not been successfully monitored using classic cellular protein interaction techniques. The PathHunter® Dimerization assay platform enables you to measure these interactions on a cell surface and is ideal for lead identification, quality control and development of neutralizing antibody (Nab) assays for a variety of biologics, including bi-specific antibodies. View Validation Data »
  View List of Targets
See How it Works

Assay Benefits & Highlights

  • Functional target specific response
  • Simple one-step, plate-treat-read protocol
  • Validated for the development of biologics
  • Flexible - use for screening, potency and Nab assays

Dimerization Assay Principle

The two target receptors are tagged with ProLink™ (PK) or Enzyme Acceptor (EA). Upon ligand-induced activation, the receptors dimerize forcing the two β-gal components to complement and create an active enzyme. Active β-gal generates a chemiluminescent signal in the presence of substrate.

Screen & optimize peptides, antibodies or even small molecules

Profile & optimize bi-specific antibodies Create cell-based assays for heterodimer pairs based on native receptor biology


Cell LineLigandPart No.eXpress Kit
U2OS BMP - 7 93-0906C3
U2OS TGF-β1 93-0889C3 93-0889E3CP5S
HEK 293 IL17A 93-0931C1 93-0931E1CP7S
U2OS Recombinant Human Neuregulin-1 Beta 2 93-0961C3 93-0961E3CP5S
U2OS GDF-2 93-0962C3 93-0962E3CP22S
U2OS GDF-2 93-0963C3 93-0963E3CP0S
U2OS GDF-2 93-0964C3 93-0964E3CP22S
HEK 293 IL-3 93-0969C1
U2OS Recombinant Human Heregulinβ-1 93-0960C3 93-0960E3CP5S
U2OS Erythropoietin 93-0965C3 93-0965E3CP0S
U2OS IL-5 93-0972C3 93-0972E3CP0S
U2OS IL-10 93-0985C3 93-0985E3CP0S
U2OS IL-4 93-0988C3 93-0988E3CP5S
U2OS Recombinant Human EGF 93-0989C3 93-0989E3CP5S
U2OS IL-29 93-0993C3 93-0993E3CP5S
U2OS IL-17 (IL-17A) 93-0999C3 93-0999E3CP0S
DLD1 IL-7 93-0997C13 93-0997E13CP0S
U2OS IL-2 93-0998C3 93-0998E3CP5S
HEK 293 VEGF-121 93-0996C1 93-0996E1CP0S
U2OS IL-13 93-1000C3 93-1000E3CP5S
HEK 293 IL-13 93-1001C1 93-1001E1CP0S
U2OS IL-31 93-1002C3 93-1002E3CP5S
U2OS IL-2 93-1003C3 93-1003E3CP0S
DLD1 TSLP 93-1019C13 93-1019E13CP25S
HEK 293 IFN-beta 93-1097C1
HEK 293 IL-11 93-1028C1
HEK 293 IL-22 93-1026C1 93-1026E1CP7S
HEK 293 IL-9 93-1036C1
HEK 293 TPO 93-1108C1
U2OS Activin A 93-1072C3 93-1072E3CP5S
U2OS Activin B 93-1069C3 93-1069E3CP5S
U2OS Activin B 93-1047C3 93-1047E3CP5S
U2OS BMP-4 93-1037C3 93-1037E3CP5S
U2OS BMP-4 93-1038C3
U2OS BMP-4 93-1006C3 93-1006E3CP0S
U2OS BMP-6 93-1010C3 93-1010E3CP0S
U2OS BMP-6 93-1052C3
U2OS BMP-6 93-1053C3
U2OS Recombinant Human HGF 93-1063C3
U2OS M-CSF 93-1061C3 93-1061E3CP5S
U2OS GM-CSF 93-1078C3 93-1078E3CP22S
U2OS Recombinant Human EGF 93-1051C3 93-1051E3CP14S
U2OS Heregulin β1 93-1125C3
U2OS Recombinant Human Neuregulin-1 Beta 2 93-1042C3
U2OS FGF-18 93-1091C3
U2OS FGF-18 93-1055C3
U2OS IFN-g 93-1098C3 93-1098E3CP5S
U2OS IL-12 93-1041C3 93-1041E3CP0S
U2OS IL-17E 93-1150C3
U2OS TNFα (human) 93-1068C3 93-1068E3CP5S
U2OS IL-18 93-1044C3 93-1044E3CP5S
U2OS IL-18 93-1131C3
U2OS IL-1α 93-1032C3 93-1032E3CP5S
U2OS IL-33 93-1067C3 93-1067E3CP5S
U2OS IL-26 93-1020C3 93-1020E3CP0S
U2OS IL-24 93-1027C3 93-1027E3CP0S
U2OS IL-21 93-1035C3 93-1035E3CP0S
U2OS IL-23 93-1007C3 93-1007E3CP0S
U2OS IL-27 93-1119C3
U2OS IL-6 93-1045C3 93-1045E3CP5S
U2OS Leptin 93-1107C3
U2OS Oncostatin M 93-1056C3 93-1056E3CP5S
U2OS Anti-PD1 Antibody [NAT105] 93-1130C3
U2OS Anti-PD-L1 antibody 93-1129C3
U2OS GDF-11 93-1046C3 93-1046E3CP5S
U2OS TGF-β1 93-1122C3
U2OS GDF-11 93-1012C3 93-1012E3CP5S
U2OS Anti-TIM3 Antibody [344801] 93-1082C3 93-1082E3CP5S
U2OS Anti-VISTA Antibody [730804] 93-1079C3 93-1079E3CP5S
U2OS MIS/AMH 93-1169C3